| |
| | Hairy cell leukemia |
 | | For patients with advanced hairy cell leukemia treated with cladribine (2-chlorodeoxyadenosine, 2-CdA), pentostatin, or interferon alfa, the survival rate appears to be greater than 85% at 5 years after the initiation of any one of these therapies.[1,2] |
 | | the vast majority of patients with hairy cell leukemia.[16] There is usually little or no change in the bone marrow after splenectomy, and virtually all patients have progressive disease within 12 to 18 months. |
 | | Saven A, Burian C, Adusumalli J, et al.: Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. |
| cancerweb.ncl.ac.uk /cancernet/101651.html (1855 words) |
|